Back

Positive hemodynamic effects of CXL-1427, a novel nitroxyl prodrug in advanced heart failure patients.

21 May 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Late Breaking Trials I: Focus on acute heart failure Acute Heart Failure HFA Premium Access HEART FAILURE 2016

About the speaker

Photo
Professor Veselin Mitrovic

Kerckhoff-Clinic, Nauheim (Germany)

12 More presentations in this session

Presentation thumbnail
Bi treatment with hydralazine/nitrates versus placebo in africans admitted with acute heart failure (BA-HEF).
Professor K. Sliwa (Cape Town, ZA)
Presentation thumbnail
Discussion: BA-HEF.
Video
Presentation thumbnail
RELAX-REPEAT: a multicentre, prospective, randomised, double-blind study evaluating the safety and tolerability of repeat doses of serelaxin in patients with chronic heart failure.
Professor J. Teerlink (San Francisco, US)
Slides Video
Presentation thumbnail
Discussion: RELAX-REPEAT.
Video
Presentation thumbnail
Discussion: CXL-1427.
Video

Access the full session

Session thumbnail
Late Breaking Trials I: Focus on acute heart failure

The Event

Event poster

HEART FAILURE 2016

21 May - 24 May 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources